Drugs / JK06
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06667960 | Oct 2024 → Apr 2028 expected | cancer | Salubris Biotherapeutics Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Results 信立泰抗癌新药JK06最新临床试验数据亮相ASCO，在晚期复发性/难治性实体瘤患者中展现良好安全性与疗效 salubris.com ↗
近日，信立泰收到子公司美国 Salubris Biotherapeutics, Inc.的通知，其在美国临床肿瘤学会（ASCO）年会上公布了JK06的I/II期的最新临床进展数据。 |
| 2026-05-30 | Salubris Biotherapeutics Inc | Results Salubris Biotherapeutics Presents Updated Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate, at the American Society for Clinical Oncology salubrisbio.com ↗ |
| 2026-04-21 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Results 信立泰抗癌新药JK06最新临床试验数据亮相AACR，在非小细胞肺癌与乳腺癌患者中展现良好安全性与疗效 salubris.com ↗
其在美国癌症研究协会（AACR）2026年年会上公布了JK06的1/2期扩展队列数据。 |
| 2026-04-17 | Salubris Biotherapeutics Inc | Results Salubris Biotherapeutics Announces Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate, at the American Association for Cancer Research Conference salubrisbio.com ↗
JK06 continues to demonstrate encouraging and durable efficacy among heavily pre-treated metastatic solid tumors. |
| 2025-10-18 | Salubris Biotherapeutics Inc | Results Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress salubrisbio.com ↗
Key efficacy findings among the 29 response-evaluable patients include: 6 patients attained confirmed partial responses (PRs) (21%). |
| 2024-08-05 | Salubris Biotherapeutics Inc | Regulatory Salubris Biotherapeutics Announces European Medicines Agency Approval to Initiate a Phase 1 Clinical Trial of JK06, a 5T4-Targeted ADC, in Solid Tumors salubrisbio.com ↗
today announced it has received approval from the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of JK06 in a basket of solid tumors known to express 5T4. |
| 2024-04-22 | Salubris Biotherapeutics Inc | Regulatory Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update salubrisbio.com ↗
Clinical trial application filed for JK06, SalubrisBio’s first-in-class biparatopic ADC |
All press releases naming this drug 11 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JK06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06667960 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT06667960 ↗ |